Immuneering

In order to ensure that patients receive the safest and most effective medicines possible, it is often necessary to compare medicines and assess the extent to which they are similar in their clinical impact.

Immuneering offers careers on a team advancing Deep Cyclic Inhibition to improve cancer treatment and patient outcomes.

Virtual poster presented at AACR special conference targeting RAS on March 7, 2023

IMM-1-104 is a novel, allosteric dual-MEK inhibitor designed to block pathway reactivation by disrupting phosphorylation of both MEK and ERK and has a short plasma drug half-life.

For more than 20 years, Copaxone (glatiramer acetate, Teva), a non-biological complex drug, has been a safe and effective treatment option for multiple sclerosis. In 2016, a follow-on glatiramer acetate product (FOGA, Synthon) was approved in the EU.

Copaxone is a non-biological complex drug (NBCD) for the treatment of multiple sclerosis. Recently, differently manufactured follow-on glatiramoid drug products (FOGAs) purported to be equivalent to Glatiramer acetate (GA, Copaxone -Teva) were authorised for marketing in a few countries;

Immuneering is developing Deep Cyclic Inhibitors to outpace cancer adaptation, improve durability, and preserve patient quality of life in MAPK-driven cancers.

Immuneering Corporation’s Privacy Policy describes its privacy practices and use of information related to the www.immuneering.com website.

Immuneering Corporation’s Terms of Use describe the terms and conditions for using its website.

GitHubRepository owner